Renovo

Renovo is a biopharmaceutical product company and a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.

In a comprehensive programme of Phase I/II clinical trials Renovo's lead drug, Juvista, has demonstrated statistically significant results in improving the appearance of scars in the skin, which alone represents a multi-million dollar market of unmet medical need.

Renovo aims to be first to market with a pharmaceutical drug in the US and Europe to prevent and reduce scarring. There are currently no approved pharmaceuticals available in the US or Europe for this purpose.

Renovo has an exceptional team of highly experienced and innovative scientists and clinicians. Based in Manchester, UK, at the heart of a thriving centre for pharmaceutical research, Renovo has built a portfolio of drugs that have reached phase 2 and phase 3 of clinical development, as well as a rich pipeline at all stages of pre-clinical R&D.

A high performance culture of innovation as well as scientific and clinical excellence has allowed Renovo to pursue pioneering programmes of drug discovery and development in the rapidly evolving fields of scar prevention, wound healing and tissue regeneration. Renovo has its own fully staffed Clinical Trials Unit and a productive development team focussed on wound and scar biology, pharmacology, genomics and proteomics.

Type:	NORMAL
Address:	Core Technology Facility 48 Grafton Street Manchester M13 9XX
Website:	www.renovo.com
Phone:	+44 (0) 161 276 7100
Fax:	+44 (0) 161 276 7200
Email:	info@renovo.com